EDITORIAL SECTION

Articles

Cell and Gene Therapy's Trillion-Dollar Reckoning Is Here

Cell and gene therapies can cure diseases once thought untreatable Yet a string of commercial collapses now suggests that curing the patient and sustaining the business are two very different challenges and the industry is confronting the gap at last

EU Pharma Reform 2025 Explained: What Market Access Leaders Must Know for 2026-2029

What if your EU market exclusivity depends on launching your medicine in every member state and proving its realworld value This is no longer hypothetical The historic Pharma Reform agreement of the Council of the EU of March is the first major revision of pharmaceutical legislation in more than years It will have a significant impact on the way businesses will enter the market set their prices...

Generative AI in Pharma: Scaling Productivity without Compromising

Most enterprise technologies enter a pharmaceutical company through a single door A manufacturing execution system arrives at a site A clinical data platform arrives in development Governance follows the deployment because there is a deployment to govern Generative AI did not behave this way It reached medical writers regulatory managers safety officers market access teams and commercial staff sim...

Patient-Centered Approaches In Pharma: From R&D to the Future

The pharmaceutical industry is undergoing a paradigm shift towards patientcentered approaches recognizing the importance of considering patient perspectives throughout the drug development and healthcare delivery process

Pharmaceutical Marketing in the Digital Age: Strategies and Challenges

Currently there is a great advancement in the use of technological solutions particularly under the modern pharma digital era Therefore with increase in knowledge dissemination through internet among the citizenry due to enhanced technology

Smarter, Faster, Cheaper: The Quiet Revolution in Pharma's First Half of 2026

If you took a step back to look at the pharmaceutical industry during the first six months of one thing became obvious very quickly The old rules of global drug manufacturing were quietly rewritten For decades major lowcost production centers were viewed mostly as highvolume factories for basic

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases

Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys